- Male or female at least 18 years of age
- A diagnosis of ESKD undergoing maintenance dialysis for at least 12 weeks
- Serum hs-CRP ≥ 2.0 mg/L
- A diagnosis of diabetes mellitus OR ASCVD
Atherosclerotic Cardiovascular Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
NCT05485961 | Phase 2 | Interventional
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on CV outcomes and safety in subjects with end stage kidney disease (ESKD) undergoing maintenance dialysis with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
Peninsula Kidney Associates
Hampton,Virginia,United States,23666
Study Eligibility Criteria
- Subjects who participated in Part 1 (phase 2b) are not eligible to participate in Part 2 (phase 3)
- Concomitant use of systemic immunosuppressant drugs
- Abnormal LFTs
- Any life-threatening disease expected to result in death within 12 months
- A history of GI perforation, inflammatory bowel disease (except fully excised ulcerative colitis), or peptic ulcer disease
Additional Studies
Additional studies can be found at ClinicalTrials.gov